loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Nifty500 Healthcare Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Poly Medicure Ltd. 25 May 2026 17:33 PM

Q4FY26 & FY26 Result Announced for Poly Medicure Ltd.

Healthcare Supplies company Poly Medicure announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Revenue from Operations: For Q4FY26, Revenue from Operations stood at Rs 53,451.14 lakh, registering a growth of 8.28% QoQ compared to Rs 49,365.55 lakh in Q3FY26, and a strong increase of 21.25% YoY from Rs 44,082.82 lakh in Q4FY25.
  • Annual Revenue from Operations: For the full year FY26, Revenue from Operations amounted to Rs 1,87,525.92 lakh, reflecting a 12.30% YoY growth from Rs 1,66,983.16 lakh in FY25.
  • Total Income: In Q4FY26, Total Income reached Rs 55,226.79 lakh, up by 6.22% QoQ from Rs 51,991.89 lakh in Q3FY26, and higher by 18.73% YoY compared to Rs 46,513.77 lakh in Q4FY25.
  • Annual Total Income: For FY26, Total Income stood at Rs 1,99,534.14 lakh, an increase of 13.44% YoY against Rs 1,75,895.92 lakh in FY25.
  • Net Profit: Net Profit for Q4FY26 was reported at Rs 6,504.10 lakh, reflecting a decline of 8.15% QoQ from Rs 7,080.89 lakh in Q3FY26, and a decrease of 29.18% YoY from Rs 9,183.42 lakh in Q4FY25.
  • Annual Net Profit: For FY26, Net Profit stood at Rs 32,072.99 lakh, a slight drop of 5.27% YoY compared to Rs 33,855.72 lakh in FY25.
  • Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was Rs 8,993.90 lakh, and for the full year FY26, it amounted to Rs 36,721.58 lakh.

Standalone Financial Highlights:

  • Revenue from Operations: Revenue from Operations for Q4FY26 came in at Rs 44,301.49 lakh, up by 5.77% QoQ from Rs 41,886.15 lakh in Q3FY26, and growing by 5.24% YoY from Rs 42,096.94 lakh in Q4FY25.
  • Annual Revenue from Operations: For FY26, Annual Revenue from Operations was Rs 1,66,246.48 lakh, showing an increase of 3.79% YoY against Rs 1,60,179.98 lakh in FY25.
  • Total Income: Total Income for Q4FY26 was Rs 45,813.68 lakh, registering an increase of 2.17% QoQ against Rs 44,841.37 lakh in Q3FY26, and a 2.97% growth YoY from Rs 44,491.80 lakh in Q4FY25.
  • Annual Total Income: For FY26, Annual Total Income stood at Rs 1,78,238.25 lakh, growing 5.37% YoY from Rs 1,69,157.22 lakh in FY25.
  • Net Profit: Net Profit for Q4FY26 was Rs 8,062.17 lakh, increasing by 2.86% QoQ from Rs 7,838.38 lakh in Q3FY26, but declining by 6.97% YoY from Rs 8,666.02 lakh in Q4FY25.
  • Annual Net Profit: For FY26, Net Profit was Rs 33,598.49 lakh, reflecting a marginal growth of 1.40% YoY from Rs 33,133.47 lakh in FY25.
  • Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was Rs 8,125.00 lakh, and for the full year FY26, it stood at Rs 33,621.11 lakh.

Business & Segment Highlights:

  • Dividend: The Board of Directors recommended a dividend of Rs 3.50 (70%) per Equity Share of Rs 5 each for the financial year 2025-26, subject to the approval of shareholders.
  • Segment Performance: The company's operations fall entirely under "Medical Devices", which is considered to be the only reportable segment by the management. Therefore, overall financial results fully reflect the performance of this single segment.
  • Fund Raising (QIP): The company successfully raised Rs 99,999.98 lakh during the previous year by issuing 53,19,148 equity shares of Rs 5 each at a premium of Rs 1,875 each (issue price of Rs 1,880 per share) to Qualified Institutional Investors on a QIP basis.
  • Strategic Acquisitions:
    • The Group acquired 90% economic rights in the Pendracare Group (comprising Pendracare Holdings BV and Welling Medical BV) through RISOR Holding BV.
    • The Group also acquired 100% economic rights in Medistream SA, Switzerland (comprising Citieffe group) through its wholly owned subsidiary company Poly Medicure BV Netherlands.
  • Resolution Plan Approval: The Hon’ble NCLT of Allahabad approved the company's resolution plan for Himalayan Mineral Water Private Limited (Target Company). An amount of Rs 3,316.00 lakh has been deposited to acquire 100% equity shareholding in the target company.
  • Auditor Appointments: The company approved the re-appointment of M/s. PricewaterhouseCoopers Services LLP and M/s Oswal Sunil & Co. (Chartered Accountants) as Internal Auditors for FY27.

Result PDF

Pharmaceuticals company Blue Jet Healthcare announced Q4FY26 & FY26 results

Q4FY26 Financial Highlights:

  • Revenue from Operations: Stood at Rs 2,347 million in Q4FY26, compared to Rs 1,924 million in Q3FY26 (up 22% QoQ) and Rs 3,404 million in Q4FY25 (down 31.1% YoY).
  • EBITDA: Stood at Rs 713 million (30% margin), compared to Rs 469 million (24% margin) in Q3FY26 (up 52% QoQ) and Rs 1,400 million (41% margin) in Q4FY25 (down 49.1% YoY).
  • Profit After Tax (PAT): Stood at Rs 643 million (27% margin), compared to Rs 402 million (21% margin) in Q3FY26 (up 60% QoQ) and Rs 1,101 million (32% margin) in Q4FY25 (down 41.6% YoY).
  • Gross Margin: Stood at 56.4% in Q4FY26, compared to 51.7% in Q3FY26 and 54.9% in Q4FY25.

FY26 Financial Highlights:

  • Revenue from Operations: Stood at Rs 9,473 million, compared to Rs 10,300 million in FY25 (down 8% YoY).
  • EBITDA: Stood at Rs 2,941 million (31% margin), compared to Rs 3,777 million (37% margin) in FY25 (down 22.1% YoY).
  • Profit After Tax (PAT): Stood at Rs 2,478 million (26% margin), compared to Rs 3,052 million (30% margin) in FY25 (down 18.8% YoY).
  • Gross Margin: Stood at 54% in FY26, compared to 55.2% in FY25.
  • Other Income: Increased to Rs 687 million in FY26 from Rs 463 million in FY25, primarily driven by foreign exchange gains.

Business Highlights:

  • Segment Performance:
    • Contrast Media Intermediates: Contributed 52.50% to total revenue in FY26. The company supplies critical starting intermediates and advanced intermediates, holding relationships with 3 of the largest global manufacturers.
    • Pharma Intermediates & APIs: Contributed 31.60% to total revenue in FY26. Performance in FY26 was impacted by lower sales, though the company noted that de-stocking and inventory normalization by customers is now complete.
    • High Intensity Sweeteners: Contributed 13.90% to total revenue in FY26, serving over 300 customers globally.
  • Strategic Updates:
    • Projects: The ground-breaking ceremony for the Vizag project is completed, and project activities have commenced. Civil construction for the new R&D centre in Hyderabad has started, with completion expected by September 2026.
    • Commercial Wins: Received trial orders in Advanced Contrast Media from a new Japanese customer.
    • Operational Focus: The company continues to focus on forward integration into more advanced intermediates for Contrast Media, operational efficiency, and maintaining long-standing customer relationships.

Result PDF

Healthcare Facilities company Narayana Hrudayalaya announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Revenue from operations: For Q4FY26, revenue stood at Rs 25,938.06 million, reflecting a strong YoY growth of 75.80% from Rs 14,754.38 million in Q4FY25, and a QoQ increase of 20.58% from Rs 21,511.70 million in Q3FY26. Annual revenue for FY26 was Rs 78,960.35 million, marking a 44.01% YoY growth compared to Rs 54,829.77 million in FY25.
  • Total income: Total income for Q4FY26 was Rs 26,230.35 million, up 74.60% YoY against Rs 15,022.80 million in Q4FY25, and an increase of 20.63% QoQ from Rs 21,743.76 million in Q3FY26. The total income for FY26 reached Rs 79,962.54 million, up 43.43% YoY from Rs 55,750.12 million in FY25.
  • EBITDA: Q4FY26 EBITDA grew by 40.21% YoY to Rs 5,392.12 million from Rs 3,845.63 million in Q4FY25, and increased 38.10% QoQ from Rs 3,904.43 million in Q3FY26. Annual EBITDA for FY26 stood at Rs 17,168.91 million, up 25.46% YoY from Rs 13,684.22 million in FY25.
  • Profit after tax (Net profit): Net profit for Q4FY26 was Rs 2,239.92 million, showing a YoY growth of 13.54% from Rs 1,972.86 million in Q4FY25, and a 76.67% QoQ jump from Rs 1,267.85 million in Q3FY26. For FY26, the net profit stood at Rs 8,059.79 million, representing a slight YoY increase of 1.94% compared to Rs 7,906.31 million in FY25.

Standalone Financial Highlights:

  • Revenue from operations: Q4FY26 revenue was Rs 10,440.50 million, registering a YoY increase of 13.60% from Rs 9,190.27 million in Q4FY25, and a QoQ growth of 7.77% from Rs 9,687.81 million in Q3FY26. Annual revenue for FY26 grew by 10.72% YoY to Rs 39,751.41 million from Rs 35,901.22 million in FY25.
  • Total income: Total income for Q4FY26 stood at Rs 11,711.09 million, up 14.18% YoY against Rs 10,256.91 million in Q4FY25, and up 18.94% QoQ from Rs 9,846.32 million in Q3FY26. For FY26, total income was Rs 41,515.75 million, up 11.23% YoY from Rs 37,322.85 million in FY25.
  • EBITDA: Q4FY26 EBITDA surged 25.23% YoY to Rs 3,536.74 million from Rs 2,824.31 million in Q4FY25, and increased 60.31% QoQ from Rs 2,206.15 million in Q3FY26. Annual EBITDA for FY26 stood at Rs 10,158.82 million, up 24.85% YoY from Rs 8,137.02 million in FY25.
  • Profit after tax (Net profit): Net profit for Q4FY26 stood at Rs 2,021.25 million, reflecting a YoY growth of 26.35% from Rs 1,599.76 million in Q4FY25, and an increase of 166.88% QoQ from Rs 757.37 million in Q3FY26. Annual net profit for FY26 stood at Rs 5,031.13 million, showing a 16.69% YoY growth from Rs 4,311.42 million in FY25.

Business Highlights:

  • Segment-wise Performance:
    • Medical and Healthcare related services: For Q4FY26, the segment's revenue from operations was Rs 25,019.74 million, reflecting an increase of 66.80% YoY and 20.88% QoQ. Full-year FY26 revenue reached Rs 76,886.87 million, up 37.09% YoY from Rs 56,085.18 million in FY25.
    • Others: Q4FY26 revenue from operations was Rs 1,336.74 million, marking a multi-fold YoY growth of 621.12% and a 9.90% QoQ growth. Annual FY26 revenue for this segment surged by 1132.42% YoY to Rs 3,856.50 million.
  • Corporate and Strategic Updates:
    • Dividend: The Board of Directors recommended a final dividend of Rs 4.50/- per share for FY26.
    • Fund Raising: The Board resolved to seek enabling approval from shareholders for issuing Debt Securities, including Non-Convertible Debentures (NCDs), for an amount not exceeding Rs 1,500 crore in a financial year in one or more series/tranches on a private placement basis.
    • Major Acquisition: Narayana Hrudayalaya UK Ltd, a wholly-owned subsidiary of Health City Cayman Islands Limited, successfully acquired 100% equity shares in Practice Plus Group Hospitals Limited, UK for a total consideration of GBP 188.78 million (Rs 22,009.69 million). The transaction was completed on November 6, 2025.
    • Merger and Restructuring: The Board approved the Scheme of Arrangement for the merger of Meridian Medical Research & Hospital Ltd. (MMRHL) into the Company, with an appointed date of April 1, 2024. Similarly, a scheme to demerge the clinical services of NH Integrated Care Private Limited (NHIC) into the Company was also approved.
    • Business Transition: The business operations and control of Shri Mata Vaishno Devi Narayana Superspeciality Hospital were transferred to Shri Mata Vaishno Devi Charitable Society (SMVDCS) effective April 1, 2026. The Company’s subsidiary will now continue to provide management and consultancy support.
    • New Incorporation: The Company incorporated a wholly-owned subsidiary, Narayana Healthcare North Private Limited (NHNPL), on January 16, 2026.

Emmanuel Rupert, Managing Director & Group CEO, Narayana Hrudayalaya, said: “FY26 marked an important milestone in the company’s journey with the successful acquisition of the hospital business of Practice Plus Group in November 2025. By the close of the financial year, the acquired entity had completed close to two quarters within NH, and integration is progressing in line with management expectations.

We are pleased to report the highest-ever revenue at the Group level in the fourth quarter with all our geographies performing well. The India business saw positive outcomes from its domestic focus, transformation initiatives, high-value procedures, and efficient usage of technology, delivering the highest-ever revenue and profitability for the quarter. Narayana One Health continues to strengthen the integrated healthcare delivery model, and the expanding clinic and insurance network has enhanced patient outreach, contributing positively to the overall India business. Our Cayman business delivered another year of robust performance and benefited from the addition of Health City Camana Bay and sustained demand across specialties. One Health Cayman, our integrated health insurance platform, continues to further strengthen patient access and affordability within the ecosystem. We thank the investor community for their faith in us and remain confident of delivering on expectations for the upcoming year.”

Result PDF

Healthcare Facilities company Fortis Healthcare announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Revenue from Operations: For Q4FY26, the revenue stood at Rs 2,36,467 lakh, reflecting a YoY growth of 17.8% from Rs 2,00,720 lakh in Q4FY25, and a QoQ increase of 4.4% from Rs 2,26,501 lakh in Q3FY26. Annual revenue for FY26 was Rs 9,12,784 lakh, marking a 17.3% YoY growth compared to Rs 7,78,275 lakh in FY25.
  • Total Income: Total income for Q4FY26 was Rs 2,36,906 lakh, up 16.9% YoY against Rs 2,02,700 lakh in Q4FY25, and an increase of 4.2% QoQ from Rs 2,27,330 lakh in Q3FY26. The total income for FY26 reached Rs 9,17,850 lakh, up 16.9% YoY from Rs 7,84,969 lakh in FY25.
  • EBITDA: Q4FY26 EBITDA grew by 17.9% YoY to Rs 53,672 lakh from Rs 45,527 lakh in Q4FY25, and increased 4.4% QoQ from Rs 51,394 lakh in Q3FY26. Annual EBITDA for FY26 stood at Rs 2,13,564 lakh, up 29.0% YoY from Rs 1,65,488 lakh in FY25.
  • Net Profit: Net profit for the period (from continuing operations) in Q4FY26 was Rs 27,119 lakh, showing a strong YoY growth of 44.2% from Rs 18,802 lakh in Q4FY25, and a 37.4% QoQ increase from Rs 19,740 lakh in Q3FY26. For FY26, the net profit stood at Rs 1,06,419 lakh, representing an increase of 31.5% YoY compared to Rs 80,938 lakh in FY25.

Standalone Financial Highlights:

  • Revenue from Operations: Q4FY26 revenue was Rs 46,073 lakh, registering a YoY increase of 18.6% from Rs 38,847 lakh in Q4FY25, and a QoQ growth of 4.0% from Rs 44,293 lakh in Q3FY26. Annual revenue for FY26 grew by 24.0% YoY to Rs 1,79,250 lakh from Rs 1,44,589 lakh in FY25.
  • Total Income: Total income for Q4FY26 stood at Rs 47,726 lakh, up 15.4% YoY against Rs 41,346 lakh in Q4FY25, and up 3.9% QoQ from Rs 45,915 lakh in Q3FY26. For FY26, total income was Rs 1,95,768 lakh, up 19.0% YoY from Rs 1,64,444 lakh in FY25.
  • EBITDA: Q4FY26 EBITDA surged 32.2% YoY to Rs 12,684 lakh from Rs 9,595 lakh in Q4FY25, and increased 10.3% QoQ from Rs 11,498 lakh in Q3FY26. Annual EBITDA for FY26 stood at Rs 56,224 lakh, up 23.8% YoY from Rs 45,406 lakh in FY25.
  • Net Profit: Net profit for Q4FY26 stood at Rs 2,498 lakh, recovering from a net loss of Rs 4,223 lakh in Q4FY25, while it saw a decline of 12.0% QoQ from Rs 2,840 lakh in Q3FY26. Annual net profit for FY26 stood at Rs 23,034 lakh, reflecting an exceptional 261.1% YoY growth from Rs 6,379 lakh in FY25.

Business Highlights:

  • Healthcare Segment: For Q4FY26, the healthcare segment's revenue from operations was Rs 2,02,323 lakh, up 18.9% YoY and 4.4% QoQ. Segment profit for Q4FY26 grew 18.1% YoY and 7.5% QoQ to Rs 35,475 lakh. Full-year FY26 revenue reached Rs 7,77,269 lakh (up 19.1% YoY), while the annual segment profit stood at Rs 1,39,370 lakh (up 30.2% YoY).
  • Diagnostics Segment: Q4FY26 revenue from operations was Rs 38,726 lakh, marking an 11.1% YoY and 4.4% QoQ growth. Segment profit for Q4FY26 surged 69.2% YoY to Rs 5,561 lakh, while staying largely flat sequentially (up 0.2% QoQ). Annual FY26 revenue grew by 8.5% YoY to Rs 1,52,656 lakh, and annual segment profit witnessed an 83.9% YoY jump to Rs 24,185 lakh.

Corporate & Strategic Updates:

  • Dividend: The Board of Directors recommended a final dividend of Rs 1 per equity share (10% of face value of Rs 10 each) for the financial year 2025-26.
  • Acquisitions:
    • On January 09, 2026, the Company’s wholly-owned subsidiary, International Hospital Limited (IHL), consummated the acquisition of TMI Healthcare Private Limited (TMI), which runs the 125-bedded 'People Tree Hospital' in Bengaluru, along with its building and land, for a cumulative transaction value of Rs 43,386 lakh.
    • Fortis Hospotel Limited (FHTL) successfully acquired the entire business operations of Shrimann Superspecialty Hospital situated in Jalandhar for an overall consideration of Rs 46,190 lakh.
  • Brand & Trademark Milestones:
    • Agilus Diagnostics Limited (formerly SRL Limited) successfully secured the 'SRL' brand and allied trademarks as the highest bidder by placing a bid of Rs 8 crore in a public auction, receiving a "Certificate of Sale" from the Delhi High Court.
    • Fortis Healthcare successfully acquired the 'Fortis' brand and allied trademarks as the highest bidder in a public auction for a total bid price of Rs 20,000 lakh.
  • Mergers and Re-structuring: The Composite Scheme of Amalgamation of Fortis Emergency Services Limited, Birdie & Birdie Realtors Private Limited, Fortis Health Management (East) Limited and Fortis Cancer Care Limited with Fortis Hospitals Limited (FHsL) received NCLT approvals and became effective from March 01, 2026.
  • Operations & Maintenance (O&M): The Company entered into an O&M Services agreement with Gleneagles Healthcare India Private Limited to manage the operations of five hospitals and one clinic, effective July 23, 2025.
  • Open Offers: The Fortis Open Offer and Malar Open Offer initiated by the Acquirer (Northern TK Venture Pte Ltd / IHH Healthcare Berhad) were successfully completed on November 10, 2025.
  • Labour Code Impact: The new Government of India Labour Codes resulted in a one-time provision increase for employee benefits amounting to Rs 5,518 lakh, which was recognized as an 'Exceptional Item' in the FY26 consolidated financial statements.

Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said: “We have witnessed a steady business performance in Q4 enabling us to end the year on a healthy note. Our hospital business, which now contributes 85% to our overall revenues continues to do well. We have maintained our investment momentum in augmenting medical equipment and technology, adding to our clinical depth and expanding key medical programs. For FY26, our top 6 specialties have grown 19% notably amongst them being Renal Sciences and Orthopedics, which witnessed a growth of 22% and 21%, respectively.”

“I’m also pleased to share that the year gone by has seen network expansion in our key geographies through brownfield initiatives and acquisitions. As part of our inorganic growth strategy, we added ~500 beds to our network through the acquisition of People Tree Hospital, Bengaluru; the Shrimann Hospital in Jalandhar, Punjab and with a long-term lease arrangement for the Greater Noida Hospital in Delhi NCR. We continue to progress on our brownfield expansion plans and actively evaluate further inorganic growth opportunities within our focus geographic clusters.”

Result PDF

Pharmaceuticalscompany Torrent Pharmaceuticals announced Q4FY26 & FY26 results

Q4FY26 Financial Highlights:

  • Revenue from operations: The company reported total revenue from operations of Rs 2,735 crore for Q4FY26, compared to Rs 2,433 crore in Q4FY25 (YoY increase of ~12.4%) and Rs 2,599 crore in the preceding quarter (QoQ increase of ~5.2%).
  • Profit After Tax: Net profit for Q4FY26 was Rs 467 crore, compared to Rs 474 crore in Q4FY25 (YoY decrease of ~1.5%) and Rs 577 crore in the preceding quarter (QoQ decrease of ~19.1%).
  • Earnings Per Share (EPS): Basic and diluted EPS for Q4FY26 stood at Rs 13.80, compared to Rs 14.00 in Q4FY25 and Rs 17.04 in the preceding quarter.

FY26 Financial Highlights:

  • Revenue from operations: Total revenue from operations for FY26 was Rs 10,712 crore, compared to Rs 9,682 crore in FY25 (YoY increase of ~10.6%).
  • Profit After Tax: Net profit for FY26 was Rs 2,192 crore, compared to Rs 1,888 crore in FY25 (YoY increase of ~16.1%).
  • Earnings Per Share (EPS): Basic and diluted EPS for FY26 stood at Rs 64.75, compared to Rs 55.79 in FY25.
  • Dividend: The Board has recommended a final dividend of Rs 9 per equity share (180%) of Rs 5 each, subject to approval by shareholders.

Business Highlights:

  • Segment Performance: The company operates in a single reportable segment, i.e., "Generic Formulation Business".
  • Acquisition Updates: The company completed the acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) effective January 21, 2026. Consequently, the consolidated financial results include the financial results of JB Pharma from this date.
  • Key Highlights:
    • Reported Consolidated Revenue: Rs 4,197 crore for Q4FY26 (up 42% YoY).
    • Base Business Growth: Excluding JB Pharma, the base business recorded revenue growth of 16% for the quarter and 15% for FY26.
    • Regional Performance (FY26):
      • India: Revenues at Rs 7,645 crore (up 20% YoY).
      • Brazil: Revenues at Rs 1,362 crore (up 24% YoY).
      • United States: Revenues at Rs 1,363 crore (up 24% YoY).
      • Germany: Revenues at Rs 1,249 crore (up 10% YoY).

Result PDF

Pharmaceuticals company Sun Pharmaceutical Industries announced Q4FY26 & FY26 results

Standalone Financial Highlights:

  • Revenue from Operations:
    • Q4FY26: Rs 48,872.7 million, compared to Rs 56,512.1 million in Q3FY26 (QoQ decrease of 13.52%) and Rs 71,006.5 million in Q4FY25 (YoY decrease of 31.17%).
    • FY26: Rs 206,090.2 million, compared to Rs 225,984.0 million in FY25 (YoY decrease of 8.80%).
  • Total Income:
    • Q4FY26: Rs 49,868.1 million, compared to Rs 58,676.7 million in Q3FY26 (QoQ decrease of 15.01%) and Rs 73,115.8 million in Q4FY25 (YoY decrease of 31.79%).
    • FY26: Rs 211,739.7 million, compared to Rs 233,565.4 million in FY25 (YoY decrease of 9.35%).
  • Net Profit After Tax:
    • Q4FY26: Rs 6,087.0 million, compared to Rs 7,054.4 million in Q3FY26 (QoQ decrease of 13.71%) and Rs 20,419.7 million in Q4FY25 (YoY decrease of 70.19%).
    • FY26: Rs 26,234.2 million, compared to Rs 42,280.8 million in FY25 (YoY decrease of 37.95%).

Consolidated Financial Highlights:

  • Revenue from Operations:
    • Q4FY26: Rs 145,597.5 million, compared to Rs 154,690.7 million in Q3FY26 (QoQ decrease of 5.88%) and Rs 128,155.8 million in Q4FY25 (YoY increase of 13.61%).
    • FY26: Rs 582,201.1 million, compared to Rs 520,412.5 million in FY25 (YoY increase of 11.87%).
  • Total Income:
    • Q4FY26: Rs 150,702.9 million, compared to Rs 160,993.8 million in Q3FY26 (QoQ decrease of 6.39%) and Rs 135,717.1 million in Q4FY25 (YoY increase of 11.04%).
    • FY26: Rs 604,337.6 million, compared to Rs 545,434.8 million in FY25 (YoY increase of 10.80%).
  • Net Profit for the Period/Year:
    • Q4FY26: Rs 27,140.3 million, compared to Rs 33,688.1 million in Q3FY26 (QoQ decrease of 19.44%) and Rs 21,498.8 million in Q4FY25 (YoY increase of 26.24%).
    • FY26: Rs 114,794.2 million, compared to Rs 109,290.4 million in FY25 (YoY increase of 5.04%).

Business Highlights:

  • Dividend: The Board recommended a Final Dividend of Rs 5.00 per equity share (face value Re 1/- each) for FY26. This is in addition to the interim dividend of Rs 11.00 per share paid during FY26, bringing the total dividend to Rs 16.00 per share.
  • India Formulations: Sales grew 14.8% YoY in Q4FY26 to Rs 48,359 million, accounting for 33.2% of total consolidated sales.
  • Organon Acquisition: The Group entered into a definitive agreement to acquire all outstanding shares of Organon & Co. for an enterprise valuation of USD 11.75 billion, with indicative closure by Q4FY27.
  • R&D: R&D investment for FY26 was Rs 35,540 million (6.1% of sales), with 38.7% of this spend dedicated to Innovative Medicines.
  • Financial Position: Strong balance sheet with a Net Cash position of USD 3.2 billion as of March 31, 2026.

Kirti Ganorkar, Managing Director, said: “Our full-year performance reflects several significant achievements. Sun’s 0.3 percentage point gain in the India market is our highest gain since the Ranbaxy acquisition. Our U.S. Innovative Medicines business has surpassed USD 1 billion in revenues, while Ex-US Innovative Medicines continues to demonstrate strong growth momentum. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company.”

Result PDF

Pharmaceuticals company Jubilant Pharmova announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Quarterly Performance:
    • Total Revenue from Operations: Stood at Rs 22,900 million in Q4FY26, representing a YoY growth of 18.73% from Rs 19,288 million in Q4FY25 and a QoQ increase of 7.89% from Rs 21,225 million in Q3FY26.
    • Total Income: Reached Rs 23,137 million in Q4FY26, up 19.22% YoY from Rs 19,407 million and up 7.97% QoQ from Rs 21,430 million.
    • Profit Before Tax: For Q4FY26 was Rs 1,760 million, a decrease of 14.56% YoY from Rs 2,060 million and a significant QoQ increase of 88.44% from Rs 934 million.
    • Net Profit: Stood at Rs 1,193 million in Q4FY26, compared to Rs 1,513 million in Q4FY25 (YoY decrease of 21.15%) and Rs 558 million in Q3FY26 (QoQ increase of 113.80%).
    • Total Comprehensive Income: For Q4FY26 was Rs 4,012 million, significantly higher than Rs 1,467 million in Q4FY25 and Rs 1,182 million in Q3FY26.
  • Annual Performance (FY26 vs. FY25):
    • Total Revenue from Operations: Grew to Rs 82,796 million in FY26, a YoY increase of 14.45% from Rs 72,345 million in FY25.
    • Total Income: For FY26 was Rs 83,456 million, up 14.46% YoY from Rs 72,913 million.
    • Profit Before Tax: For FY26 stood at Rs 6,141 million, reflecting a YoY decline of 37.38% from Rs 9,806 million in FY25 (FY25 profit was influenced by higher exceptional gains).
    • Net Profit: In FY26 reached Rs 3,975 million, a YoY decrease of 65.02% from Rs 11,363 million in FY25.
    • Total Comprehensive Income: For the full year FY26 was Rs 9,433 million, compared to Rs 9,213 million in FY25.

Standalone Financial Highlights:

  • Quarterly Performance (Q4FY26 vs. Q4FY25):
    • Total Revenue from Operations: For Q4FY26 was Rs 703 million, up 15.82% YoY from Rs 607 million.
    • Net Profit: For Q4FY26 reached Rs 572 million, compared to Rs 136 million in Q4FY25.
    • Annual Performance (FY26 vs. FY25):
    • Total Revenue from Operations: For FY26 stood at Rs 2,635 million, compared to Rs 2,314 million in FY25.
    • Net Profit: Reached Rs 632 million in FY26, a YoY growth of 229.17% from Rs 192 million in FY25.

Business Highlights:

  • Segment-wise Performance (FY26 Consolidated Revenue):
    • Radiopharma: Contributed Rs 36,901 million in FY26, up from Rs 33,880 million in FY25.
    • Allergy Immunotherapy: Contributed Rs 7,957 million in FY26, up from Rs 7,142 million in FY25.
    • CDMO - Sterile Injectables: Contributed Rs 18,125 million in FY26, compared to Rs 13,527 million in FY25.
    • CRDMO: Contributed Rs 12,649 million in FY26, compared to Rs 11,728 million in FY25.
    • Generics: Contributed Rs 7,735 million in FY26, up from Rs 6,853 million in FY25.
  • Dividend Recommendation: The Board of Directors has recommended a final dividend of 500%, i.e., Rs 5 per equity share of face value Re 1 each for the financial year ended March 31, 2026.
  • Sale of API Business: The company completed the sale and transfer of its Active Pharmaceutical Ingredients (API) business as a going concern on a slump sale basis to its wholly-owned subsidiary, Jubilant Biosys Limited, effective September 1, 2025. This business has been classified as "Discontinued Operations" in the standalone results.
  • Exceptional Items (FY26):
    • Gain of Rs 236 million on the sale of assets of a ceased manufacturing facility in Salisbury, Maryland, USA.
    • Remediation expenses of Rs 535 million related to the suspension of operations at the Montreal, Canada facility.
    • Incremental impact of Rs 133 million (gratuity of Rs 100 million and compensated absences of Rs 33 million) due to the notification of New Labour Codes.
    • Amortization of debt initiation costs of Rs 96 million on prepayment of a term loan.
    • Impairment of investment in an associate amounting to Rs 64 million.
  • Audit Opinion: The statutory auditors have issued an Audit Report with an unmodified opinion on the audited financial results (standalone and consolidated) for the year ended March 31, 2026.

Result PDF

Pharmaceuticals company Aurobindo Pharma announced Q4FY26 & FY26 results

Standalone Financial Highlights:

  • Total Revenue from Operations:
    • Q4FY26: Rs 27,865.5 million, compared to Rs 27,472.8 million in Q3FY26 (QoQ increase of 1.43%) and Rs 27,319.9 million in Q4FY25 (YoY increase of 2.00%).
    • FY26: Rs 1,11,717.2 million, compared to Rs 1,09,333.0 million in FY25 (YoY increase of 2.18%).
  • Total Income:
    • Q4FY26: Rs 30,006.4 million, compared to Rs 28,774.3 million in Q3FY26 (QoQ increase of 4.28%) and Rs 28,459.7 million in Q4FY25 (YoY increase of 5.43%).
    • FY26: Rs 1,17,592.5 million, compared to Rs 1,12,614.2 million in FY25 (YoY increase of 4.42%).
  • Profit After Tax (PAT):
    • Q4FY26: Rs 6,922.3 million, compared to Rs 5,820.7 million in Q3FY26 (QoQ increase of 18.93%) and Rs 4,081.7 million in Q4FY25 (YoY increase of 69.60%).
    • FY26: Rs 24,148.0 million, compared to Rs 17,467.9 million in FY25 (YoY increase of 38.24%).

Consolidated Financial Highlights:

  • Total Revenue from Operations:
    • Q4FY26: Rs 88,533.4 million, compared to Rs 86,459.0 million in Q3FY26 (QoQ increase of 2.40%) and Rs 83,821.2 million in Q4FY25 (YoY increase of 5.62%).
    • FY26: Rs 3,36,530.8 million, compared to Rs 3,17,237.3 million in FY25 (YoY increase of 6.08%).
  • Total Income:
    • Q4FY26: Rs 89,703.8 million, compared to Rs 88,335.4 million in Q3FY26 (QoQ increase of 1.55%) and Rs 85,169.3 million in Q4FY25 (YoY increase of 5.32%).
    • FY26: Rs 3,41,451.7 million, compared to Rs 3,23,455.8 million in FY25 (YoY increase of 5.56%).
  • Profit After Tax (PAT):
    • Q4FY26: Rs 9,208.4 million, compared to Rs 9,098.0 million in Q3FY26 (QoQ increase of 1.21%) and Rs 9,028.3 million in Q4FY25 (YoY increase of 1.99%).
    • FY26: Rs 35,029.7 million, compared to Rs 34,835.7 million in FY25 (YoY increase of 0.56%).

Business Highlights:

  • Segment Reporting: The company operates in only one reportable segment, 'Pharmaceuticals', in accordance with Ind AS 108, "Operating Segment".
  • Corporate Developments:
    • The Board of Directors approved a buyback of 5,423,728 fully paid-up equity shares of face value of Rs 1 each for an aggregate value not exceeding Rs 8,000.0 million on April 06, 2026. This was paid to eligible shareholders on May 07, 2026.
    • The domestic branded generic pharmaceutical formulations business was transferred to Auropharm Limited (a wholly-owned subsidiary) on a going concern basis via a slump sale effective April 01, 2026.
    • Effective January 01, 2026, Auropharm Limited acquired the non-oncology prescription formulations business from M/s Khandelwal Laboratories Private Limited for a total consideration of Rs 3,250 million.
  • Labour Codes Impact: The company recognized an incremental gratuity and leave liability aggregating to Rs 173.8 million in the Standalone financial results and Rs 653.3 million in the Consolidated financial results for the quarter ended December 31, 2025 and year ended March 31, 2026, due to the notification of Labour Codes. This has been presented as "Exceptional Items"

K. Nithyananda Reddy, Vice-Chairman & Managing Director, said: “We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio. Consistent volumes coupled with improved operating efficiencies, and disciplined execution have contributed positively to our results. With ongoing investments in capacity expansion and the stabilization of recently commercialized facilities, we remain confident in our ability to support sustainable growth and create long-term value for our stakeholders.”

Result PDF

Healthcare Facilities company Max Healthcare Institute announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Total Income: For Q4FY26, the total income was reported at Rs 2,19,072 lakh, representing a QoQ increase of 3.68% from Rs 2,11,290 lakh in Q3FY26 and a YoY increase of 11.96% from Rs 1,95,666 lakh in Q4FY25. For the full financial year FY26, total income stood at Rs 8,53,607 lakh, up by 18.82% compared to Rs 7,18,410 lakh in FY25.
  • Revenue from Operations: Stood at Rs 2,14,289 lakh for Q4FY26, compared to Rs 2,06,752 lakh in Q3FY26 (up 3.65% QoQ) and Rs 1,90,974 lakh in Q4FY25 (up 12.21% YoY). For FY26, it reached Rs 8,37,345 lakh against Rs 7,02,846 lakh in FY25.
  • Net Profit After Tax: Reported at Rs 34,222 lakh for Q4FY26, showing a QoQ growth of 13.72% from Rs 30,092 lakh in Q3FY26 and a YoY increase of 7.28% from Rs 31,900 lakh in Q4FY25. For FY26, the profit for the year was Rs 1,44,241 lakh, an increase of 34.07% YoY from Rs 1,07,588 lakh in FY25.

Standalone Financial Highlights:

  • Total Income: For Q4FY26, the total income was Rs 82,424 lakh, reflecting a QoQ increase of 3.78% from Rs 79,424 lakh in Q3FY26 and a YoY increase of 8.90% from Rs 75,685 lakh in Q4FY25. For FY26, the total income was Rs 3,17,640 lakh, up by 4.83% from Rs 3,03,014 lakh in FY25.
  • Revenue from Operations: Stood at Rs 73,290 lakh for Q4FY26, an increase of 3.09% QoQ from Rs 71,091 lakh in Q3FY26 and an increase of 11.26% YoY from Rs 65,870 lakh in Q4FY25. For FY26, it stood at Rs 2,87,445 lakh against Rs 2,66,360 lakh in FY25.
  • Net Profit After Tax: Reported at Rs 20,321 lakh for Q4FY26, up 8.70% QoQ from Rs 18,695 lakh in Q3FY26 and up 14.56% YoY from Rs 17,739 lakh in Q4FY25. For FY26, net profit reached Rs 71,661 lakh, up 2.22% YoY from Rs 70,107 lakh in FY25.

Business Highlights:

  • Segment Performance: The Group's business activity primarily falls within a single reportable business segment, namely 'Medical and Healthcare Services', and a single geographical segment, 'India'.
  • Strategic Acquisition: On May 18, 2026, the Company acquired a 58.28% controlling equity stake in Kalinga Hospitals Limited (KHL), which owns and operates a 250-bed multi-specialty hospital in Bhubaneswar, Odisha, for an aggregate cash consideration of Rs 29,797 lakh.
  • Expansion Project: The Board approved the construction of Phase-I of Max Super Specialty Hospital at Shaheed Path, Lucknow, on a 5-acre land parcel. The project will accommodate approximately 712 census beds with an expected total construction and equipment cost of ~Rs 1,400 crore (blended cost per bed of ~Rs 1.97 crore, excluding land).
  • Dividend: The Board recommended a final dividend of Rs 2/- per equity share (20% of face value of Rs 10/- each) for the financial year 2025-26, subject to member approval.
  • Corporate Restructuring and Re-classification: The Company approved the re-classification of Radiant Life Care Hospital Foundation from the ‘Promoter Group’ to the ‘Public’ category. Additionally, the merger of erstwhile Jaypee Healthcare Limited (JHL) and erstwhile Crosslay Remedies Limited (CRL) became effective from December 15, 2025.
  • Exceptional Items: Consolidated results for FY26 included a non-recurring impact of Rs 3,390 lakh due to the notification of new Labour Codes and a provision for stamp duty on merger amounting to Rs 1,434 lakh. Standalone results included an exceptional impact of Rs 1,564 lakh related to the new Labour Codes.
  • Operational Shift: The Board approved shifting the Company’s registered office from the State of Maharashtra to Gurugram, Haryana.
  • Voluntary Liquidation: The Company initiated the voluntary liquidation of its non-material wholly-owned subsidiary, MHC Global Healthcare (Nigeria) Limited

Abhay Soi, Chairman & Managing Director, Max Healthcare Institute, said: “We are pleased to announce the phased commissioning and ramp-up of brownfield expansions across Mohali, Mumbai and Delhi, representing approximately 20% capacity addition.

We also look forward to augmenting our capacity by another ~10% with the commissioning of the greenfield Gurgaon facility by the end of the year. We are also happy that the Network has delivered its 22nd consecutive quarter of year-on-year growth, with revenue increasing by 10% and operating EBITDA grew by 8%.

Further, we have completed the acquisition of a controlling stake in Kalinga Hospital, Bhubaneswar. The team has already begun integration and is working towards achieving significant operational upside. In parallel, work has commenced on the upgradation and expansion of the hospital, enabling us to extend high-quality healthcare services in a fast-growing region.”

Result PDF

Pharmaceuticals company Eris Lifesciences announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Total Revenue from Operations:
    • Q4FY26: Rs 756.56 crore compared to Rs 705.30 crore in Q4FY25 (YoY growth of ~7.3%).
    • FY26: Rs 3,129.42 crore compared to Rs 2,893.64 crore in FY25 (YoY growth of ~8.1%).
  • Net Profit for the period:
    • Q4FY26: Rs 279.10 crore compared to Rs 102.35 crore in Q4FY25 (YoY growth of ~172.7%).
    • FY26: Rs 647.51 crore compared to Rs 374.67 crore in FY25 (YoY growth of ~72.8%).

Standalone Financial Highlights:

  • Total Revenue from Operations:
    • Q4FY26: Rs 277.31 crore compared to Rs 404.77 crore in Q4FY25 (YoY decline of ~31.5%).
    • FY26: Rs 1,821.74 crore compared to Rs 1,697.75 crore in FY25 (YoY growth of ~7.3%).
  • Net Profit for the period:
    • Q4FY26: Net loss of Rs 8.60 crore compared to profit of Rs 30.47 crore in Q4FY25.
    • FY26: Rs 244.05 crore compared to Rs 77.39 crore in FY25 (YoY growth of ~215.3%).

Business Highlights:

  • Dividend Declaration: The Board declared an interim dividend of Rs 7.21 per fully paid-up equity share (at the rate of 721%) for the financial year 2026-2027. The record date is May 29, 2026, and payment will be made on or before June 19, 2026.
  • Acquisitions:
    • Swiss Parenteral Limited (SPL): Completed the acquisition of the remaining minority shares on January 16, 2026, making it a wholly-owned subsidiary.
    • Branded Probiotics Business: Completed the acquisition from Velbiom Probiotics Private Limited on March 31, 2026, for a consideration of Rs 50 crore on a slump sale basis.
  • Regulatory/Tax Impact: Due to eligibility for the concessional tax regime from the financial year 2026-27, the Company remeasured deferred tax assets and liabilities, resulting in a deferred tax credit of Rs 150 crore (consolidated) and Rs 18 crore (standalone) recognized in the Statement of Profit and Loss.
  • Exceptional Items: The Company recorded an exceptional item charge of Rs 17.24 crore (consolidated) and Rs 14.67 crore (standalone) in FY26 related to an increase in gratuity and leave liability due to the implementation of the New Labour Codes.
  • Scheme of Arrangement: The Board approved a composite scheme of arrangement to vest the "Domestic Business" of Eris Oaknet Healthcare Private Limited (EOHPL) into Eris Therapeutics Limited (ETL) and the amalgamation of Aprica Healthcare Limited (AHL) with ETL. This is subject to necessary statutory approvals.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app